Allogeneic Stem Cells Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Allogeneic Stem Cells Market is segmented By Product (Progesterone Oral, Progesterone Injection, Progesterone Suspended/Gel, Others), By Cell Origin (Bone Marrow Stem Cells, Peripheral Blood Stem Cells, Cord Blood Stem Cells, Others), By Application (Hospital, Clinic, Pharmacies, and Drug Stores)By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Allogeneic Stem Cells Market Overview

The Global Allogeneic Stem Cells Market size reached USD 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.0 billion by 2031. The global allogeneic stem cells market is expected to exhibit a CAGR of 9.6% during the forecast period (2024-2031).

 The allogeneic stem cells market experiencing significant growth in recent years. Conditioning treatment is given before an allogeneic stem cells transplant to destroy any remaining cancer cells in the body. This weakens the patient's immune system and allows the new cells to move through the bloodstream to the patient's bone marrow. For some types of blood cancers, an allogeneic stem cell transplant may work directly to destroy cancer cells, known as the graft-versus-tumor (GVT) effect. 

The global allogeneic stem cells market is driven by the factors such as the increasing prevalence of cardiovascular disorders, cancer diseases, and other chronic disorders, increasing awareness and acceptance of stem cell therapies, increasing research and development activities on allogeneic stem cells, rising demand for regenerative medicines, and technological advancements in allogeneic stem cell transplantation.

Allogeneic Stem Cells Market  Scope

To know more Insights -  Download Sample 

Allogeneic Stem Cells Market  Dynamics

Rising Demand for Regenerative Medicines Drives the Growth of the Allogeneic Stem Cells Market

The allogeneic stem cells market is experiencing substantial growth due to the rising demand for regenerative medicines. Regenerative medicine focuses on repairing or replacing damaged tissues and organs through the use of stem cells, among other advanced therapies. Allogeneic stem cells, obtained from a donor, offer several advantages in regenerative medicine applications.

Moreover, the aging population and the associated rise in age-related diseases have further fueled the demand for regenerative medicines. Allogeneic stem cell therapies offer the possibility of restoring function and improving the quality of life for patients suffering from degenerative conditions.

For instance, on September 20, 2022, Alkem Laboratories, in collaboration with Stempeutics, launched the first ‘made-in India’ off-the-shelf cell therapy product “StemOne” to treat Knee Osteoarthritis. The company announced that it received regulatory approval from the Drugs Controller General of India (DCGI) for the product. It is the first allogeneic cell therapy product to be approved for commercial use in India for Knee Osteoarthritis.

Increasing Awareness and Acceptance of Stem Cells Therapies Drive the Growth of the Market

The increasing awareness about allogeneic stem cells and their wide acceptance boosts the market share. High-profile media coverage of successful stem cell treatments and patient testimonials have helped raise awareness about the transformative potential of stem cell therapies. Positive outcomes and stories of patients who have experienced significant improvements in their conditions have captured public attention and fostered acceptance.

As awareness and acceptance of stem cell therapies continue to increase, more patients and healthcare providers are considering these treatments as viable options. This growing demand and acceptance have stimulated investments in research and development, leading to advancements in technology, manufacturing processes, and scalability, further driving the growth of the allogeneic stem cells market.

Side Effects Associated with Allogeneic Stem Cell Transplantation will Hamper the Growth of the Market

The side effects associated with allogeneic stem cell transplantation are a major factor hampering the market growth. Graft-versus-Host Disease (GVHD) is a common complication of allogeneic stem cell transplantation, where the transplanted immune cells attack the recipient's body tissues. It can range from mild to severe and can affect multiple organs, leading to significant morbidity and mortality.

Infusion reactions can occur during the transplantation process, where the recipient may experience symptoms such as fever, chills, allergic reactions, or respiratory distress. These reactions are typically managed with appropriate medications, but they can still impact patient experience and treatment outcomes

Allogeneic Stem Cells Market  Segment Analysis

The global allogeneic stem cells market is segmented based on product, cell origin, application, and region.

The Cord Blood Stem Cells Segment Accounted for Approximately 34.9% of the Allogeneic Stem Cells Market Share

The market is anticipated to grow throughout the projection due to cord blood stem cells. Cord blood contains a higher concentration of hematopoietic stem cells compared to other sources, such as bone marrow or peripheral blood. These hematopoietic stem cells are crucial for the replenishment of blood cells, making cord blood a valuable resource for hematopoietic stem cell transplantation (HSCT) in treating various blood disorders, immune deficiencies, and genetic diseases.

Cord blood stem cells have a higher tolerance for HLA mismatches, reducing the risk of graft-versus-host disease (GvHD). This compatibility advantage allows for a broader donor pool and increases the likelihood of finding suitable matches for transplantation, contributing to the popularity of cord blood stem cells.

For instance, on April 17, 2023, Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult and pediatric patients 12 years and older with hematologic malignancies planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.

Source: DataM Intelligence Analysis (2023)

Global Allogeneic Stem Cells Market  Geographical Penetration

North America Accounted for Approximately 41.6% of the Market Share in 2022, Owing to the Well-Developed Healthcare Infrastructure and Presence of Major Players 

North America has a robust and advanced healthcare infrastructure, including hospitals, clinics, research institutions, and regulatory bodies. This infrastructure supports the development, manufacturing, and distribution of progesterone products, ensuring efficient market access and availability.

The region is home to several prominent pharmaceutical companies and biotechnology firms involved in the production and marketing of progesterone products. These companies have strong research and development capabilities, extensive distribution networks, and established brand recognition, enabling them to capture a significant market share.

Source: DataM Intelligence Analysis (2023)

Allogeneic Stem Cells Market Companies

The major global players in the allogeneic stem cells market include STEMCELL Technologies Inc., Lineage Cell Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Biosolution Co. Ltd., Cynata Therapeutics Ltd., JCR Pharmaceuticals Co. Ltd., MEDIPOST Co. Ltd., MiMedx Group Inc., Osiris Therapeutics Inc., and Stempeutics Research Pvt. Ltd and others.

COVID-19 Impact on Allogeneic Stem Cells Market 

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global allogeneic stem cells market. The conflict can disrupt supply chains for allogeneic stem cell products, including stem cell sources, processing facilities, and transportation routes. Restrictions on trade and logistical challenges led to delays or difficulties in procuring and delivering allogeneic stem cells, affecting market availability.

By Product

• Adult Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells

By Cell Origin

• Bone Marrow Stem Cells
• Peripheral Blood Stem Cells
• Cord Blood Stem Cells
• Others

By Application

• Cardiovascular Disorders
• Immunological Disorders
• Cancers
• Musculoskeletal Disorders
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 12, 2023, StemCyte, a California-based regenerative therapeutics company announced that it signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide. 
• On January 09, 2023, Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, and First Light Acquisition Group (“FLAG”), a special purpose acquisition company organized to acquire or merge with one or more businesses, announced that they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs. 

Why Purchase the Report?

• To visualize the global allogeneic stem cells market segmentation based on product, cell origin, application, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of allogeneic stem cells market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global allogeneic stem cells market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

For more Biotechnology related reports, please click here